CD8A and neoplasm: A study done on humanized mouse models further demonstrated that sintilimab exerted a more potent antitumor effect compared to pembrolizumab and nivolumab, accompanied by elevated levels of CD3+ T-cells, CD8+ T-cells, and ratio of CD8+ to Treg tumor-infiltrating lymphocytes [20].